Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof
AssigneeNeurimmune Holding AG
InventorsJan Grimm, Fabrice Heitz, Feng Chen, Ioana Combaluzier
Life of this patent
Estimating the term…
Abstract
Provided are novel human islet amyloid polypeptide, also known as amylin and IAPP and proIAPP respectively, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for IAPP and/or proIAPP are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for IAPP and/or proIAPP targeted immunotherapy and diagnostics, respectively.
Claims16
An anti-islet amyloid polypeptide (IAPP) antibody or antigen-binding fragment thereof comprising a variable region comprising:
- (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 76 or a variant thereof, wherein the variant comprises two or fewer amino acid substitutions,
- (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 94 or a variant thereof, wherein the variant comprises two or fewer amino acid substitutions,
- (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 112 or a variant thereof, wherein the variant comprises two or fewer amino acid substitutions,
- (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 85 or a variant thereof, wherein the variant comprises two or fewer amino acid substitutions,
- (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 103 or a variant thereof, wherein the variant comprises two or fewer amino acid substitutions, and
- (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 121 or a variant thereof, wherein the variant comprises two or fewer amino acid substitutions.
An anti-IAPP antibody or antigen-binding fragment thereof comprising the following complementarity determining regions (CDRs):
- (a) a CDR-H1 comprising the amino acid sequence of any one of SEQ ID NO:
- 76,
- (b) a CDR-H2 comprising the amino acid sequence of any one of SEQ ID NO:
- 94,
- (c) a CDR-H3 comprising the amino acid sequence of any one of SEQ ID NO:
- 112,
- (d) a CDR-L1 comprising the amino acid sequence of any one of SEQ ID NO:
- 85,
- (e) a CDR-L2 comprising the amino acid sequence of any one of SEQ ID NO:
- 103,
- (f) a CDR-L3 comprising the amino acid sequence of any one of SEQ ID NO:
- 121.
Dependencies are inferred from the claim text.